Louisiana House Bill HB316

Louisiana 2021 Regular Session

• Introduced: 3/30/21
• Refer: 3/30/21
• Refer: 4/12/21
• Report Pass: 4/26/21
• Refer: 4/27/21
• Report Pass: 5/11/21
• Engrossed: 5/19/21
• Refer: 5/20/21
• Report Pass: 5/26/21
• Refer: 5/27/21
• Report Pass: 6/1/21
• Enrolled: 6/8/21
• Chaptered: 6/14/21
• Passed: 6/14/21

Caption

Adds mucopolysaccharidosis type I and glycogen storage disorder type II to the state's newborn screening panel (EN +$187,717 GF EX See Note)

Impact

The introduction of HB 316 signifies a legislative effort to ensure that newborns in Louisiana are screened for a broader range of genetic conditions. Given that early detection can facilitate timely treatment, this bill is expected to not only enhance health outcomes for affected infants but also potentially reduce long-term healthcare costs associated with untreated genetic disorders. The bill could lead to increased awareness and education regarding these conditions among healthcare professionals and new parents.

Summary

House Bill 316 aims to enhance the state's newborn screening panel by adding mucopolysaccharidosis type I and glycogen storage disorder type II to the list of conditions that must be tested for in newborns. By mandating these additional tests, the bill seeks to improve early detection and intervention for these serious genetic conditions, which can have significant implications for a child's health if not identified promptly. The effective date for this legislation is set for January 1, 2022, once it has successfully passed through the necessary legislative processes.

Sentiment

The reception of HB 316 appears to be overwhelmingly positive, as evidenced by the voting history where it passed unanimously in the House with 98 votes in favor and none opposed. This supports the notion that there is a strong consensus among legislators regarding the necessity of expanding the newborn screening panel. Advocates for public health view this bill as a proactive step toward improving health outcomes for vulnerable populations, particularly children.

Contention

While there are no major points of contention reported in the discussions surrounding this bill, stakeholders may have differing perspectives on the financial implications of expanding the screening panel, such as the costs associated with additional testing and potential impacts on healthcare providers. However, the supportive voting record suggests that any concerns may have been adequately addressed during the legislative process, leading to strong support from both chambers.